TABLE 2.
Univariate analyses | Multivariate analyses | |||||
---|---|---|---|---|---|---|
OR | 95% CI | p‐value | OR | 95% CI | p‐value | |
Age at inclusion | 1.01 | 0.96–1.07 | 0.67 | |||
BMI per point | 1.13 | 0.86–1.47 | 0.39 | |||
Sex | ||||||
Male | Ref | |||||
Female | 1.27 | 0.22–7.20 | 0.79 | |||
Disease duration (year) | 1.13 | 0.94–1.37 | 0.20 | 1.11 | 0.91–1.35 | 0.31 |
Disease location a | ||||||
Proctitis | 0.19 | 0.01–3.72 | 0.60 | |||
Left‐sided | 2.10 | 0.01–21.10 | 0.27 | |||
Pancolitis | Ref | 0.53 | ||||
Prior biological treatments | ||||||
Vedolizumab | 2.25 | 0.36–13.97 | 0.38 | |||
≥2 biologic therapy | 3.95 | 0.42–37.50 | 0.23 | |||
Clinical disease activityb | ||||||
SCCAI per point | 0.77 | 0.56–1.06 | 0.11 | 1.13 | 0.94–1.37 | 0.20 |
Biochemical disease activity a | ||||||
CRP (mg/L) | 1.02 | 0.94–1.11 | 0.64 | |||
Faecal calprotectin (μg/g) | 1.00 | 1.00–1.00 | 0.79 | |||
Concomitant medication a | ||||||
Corticosteroids | 2.78 | 0.47–16.35 | 0.26 |
At inclusion.